Please login to the form below

Not currently logged in
Email:
Password:

Dutch companies partner on vaccines

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio. Pepscan focuses on protein mimicking technology for the generation of immune therapeutics.

Under the agreement, Immunovo will develop its therapeutic vaccine portfolio. Immunovo will pay an undisclosed cash sum to Pepscan and Pepscan will take a minority interest in Immunovo.

"Pepscan has recently refocused its R&D programme on the application of its proprietary CLIPSTM protein mimicry technology for the generation of monoclonal antibodies and therapeutic peptides," said Wim Mol, CEO of Pepscan.

"The agreement with Immunovo allows Pepscan to fully concentrate its resources on a focused execution of its research programme. We consider Immunovo an ideal partner to enhance the value of the therapeutic vaccine portfolio we have developed over the years."

Joost van Bree, CEO of Immunovo, said: "We are very pleased with the partnership with Pepscan on the therapeutic vaccine portfolio. Pepscan created a rich development pipeline of therapeutic vaccines, of which the most advanced product is in phase II clinical development.

"We are confident that with our specific expertise we will be able to expedite the development of this portfolio, which also includes a proprietary anti-VEGF-A vaccine that could be useful for the treatment of certain cancers."

CLIPSTM (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration.

28th April 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics